

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Susumu MUTO et al.

Confirmation No.: 5597

Group Art Unit : 1614

Appl. No. : 10/516,294
(U.S. National Stage of PCT/JP03/07119)

I.A. Filed : June 5, 2003

Examiner : W. WEBB

For : NF-KB ACTIVATION INHIBITORS

**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop AMENDMENT
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98 and supplemental to the Information Disclosure Statements filed February 24, 2006, March 7, 2006, and July 26, 2006, Applicants hereby direct the Examiner's attention to the following information:

U.S. Application 11/835,978 (MUTO et al.), filed August 8, 2007 and entitled "INFLAMMATORY CYTOKINE RELEASE INHIBITOR"; Applicants note that this application is a divisional application of U.S. Application No. 10/433,619 (made of record in the Information Disclosure Statement dated February 24, 2006); and

U.S. Application 11/835,997 (MUTO et al.), August 8, 2007 and entitled "INFLAMMATORY CYTOKINE RELEASE INHIBITOR"; Applicants note that this

application is a divisional application of U.S. Application No. 10/433,619 (made of record in the Information Disclosure Statement dated February 24, 2006).


Pursuant to the U.S. Patent and Trademark Office's decision to waive the requirement under 37 C.F.R. 1.98 (a)(2)(i), copies of the listed U.S. patents and U.S. published patent applications are not enclosed herewith. Moreover, if any copies are needed, the Examiner is respectfully requested to contact the undersigned.

Copies of the above-noted information (with the exception of patents and patent publications) is attached hereto and duly listed on the attached Form PTO-1449. The Examiner is requested to initial the appropriate spaces on the attached Form and to return a copy of the initialed Form to Applicants with the next official communication in the present application.

The fee set forth in 37 C.F.R. § 1.17 (p) is provided herewith.

Should the Examiner have any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully Submitted,
Susumu MUTO et al.


Bruce H. Bernstein
Reg. No. 29,027 42,920

December 18, 2007
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191